MINNEAPOLIS, January 22, 2025--(BUSINESS WIRE)--Humanetics Corporation (Humanetics) announced today the results of its Phase 2 clinical trial of BIO 300 Oral Suspension (BIO 300) for the mitigation of ...
Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID 1) and deupirfenidone 825 mg TID and successfully demonstrated ...
Leuven, BELGIUM, Boston, MA, US – MAY 9, 2022 – 8:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback